Piper Jaffray Downgrades GPC Biotech (GPCB) to Underperform
GPCB Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Piper Jaffray downgrades GPC Biotech (Nasdaq: GPCB) from Outperform to Underperform and reduced its price target from EUR15.40 to EUR2.30. The firm expects GPC Biotech to face numerous challenges in the next year, mainly due to failed further approval of its satraplatin.
GPC Biotech AG is a biopharmaceutical company engaged in the discovery, development and commercialization of new drugs to treat cancer.
GPC Biotech AG is a biopharmaceutical company engaged in the discovery, development and commercialization of new drugs to treat cancer.
You May Also Be Interested In
- UPDATE: UBS Downgrades Avon Products (AVP) to Sell; Still Cautious Even After Sell Off
- UBS Cuts Price Target and Estimates on Analog Devices (ADI); Good Q2, But Slowing Growth in N-T
- Deutsche Bank Cuts Price Target and EPS Estimates on J. C. Penney (JCP); There's Only Two Ways This Can Go
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
